Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

DOI: https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Aaron Situ, Yixie Zhang, Ashley Bonner, Matthew A. Lunning

Blood (2022) 140 (Supplement 1): 4655–4656.

DOI: https://doi.org/10.1182/blood-2022-160216

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

DOI: https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

DOI: https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Blood (2022) 140 (Supplement 1): 2048–2050.

DOI: https://doi.org/10.1182/blood-2022-169872

Published: 2022

Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline

Blood (2022) 140 (Supplement 1): 3757–3759.

DOI: https://doi.org/10.1182/blood-2022-159594

Published: 2022

Journal Articles

A cauldron of choices

Manali Kamdar

Blood (2022) 139 (21): 3103–3104.

DOI: https://doi.org/10.1182/blood.2022015995

Published: 2022

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

DOI: https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

Journal Articles

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali Kamdar, Brian T. Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid W Merryman, Paolo Strati

Blood (2021) 138 (Supplement 1): 2495.

DOI: https://doi.org/10.1182/blood-2021-147591

Published: 2021

Journal Articles

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

Blood (2021) 138 (Supplement 1): 529.

DOI: https://doi.org/10.1182/blood-2021-149735

Published: 2021

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Blood (2021) 138 (Supplement 1): 455.

DOI: https://doi.org/10.1182/blood-2021-144308

Published: 2021

Journal Articles

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Brad Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 2444.

DOI: https://doi.org/10.1182/blood-2021-152617

Published: 2021

Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Blood (2021) 138 (Supplement 1): 2628.

DOI: https://doi.org/10.1182/blood-2021-150751

Published: 2021

Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Blood (2021) 138 (Supplement 1): 91.

DOI: https://doi.org/10.1182/blood-2021-147913

Published: 2021

Journal Articles

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

Gray Jodon, Meryl Colton, Diana Abbott, Anthony Cai, Brad M. Haverkos, Rustain Morgan, Manali Kamdar

Blood (2021) 138 (Supplement 1): 3879.

DOI: https://doi.org/10.1182/blood-2021-146613

Published: 2021

Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar

Blood (2021) 138 (Supplement 1): 3845.

DOI: https://doi.org/10.1182/blood-2021-151611

Published: 2021

Journal Articles

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander R. Coltoff, Matthew S. Davids, Peter O. Baker, Lori Leslie, Kerry A. Rogers, John N. Allan, Raul Cordoba, Alberto Lopez-Garcia, Darko Antic, John M. Pagel, Nicolas Martinez-Calle, José Antonio García-Marco, Jose‐Ángel Hernández‐Rivas, Fatima Miras, Catherine C. Coombs, Anders Österborg, Lotta Hansson, Amanda N. Seddon, Javier López Jiménez, Matthew R. Wilson, Dima El-Sharkawi, Daniel Wojenski, Shuo Ma, Talha Munir, Susana Valenciano, Erlene Seymour, Paul M. Barr, Jeffrey Pu, Piers E. M. Patten, Guilherme F. Perini, Scott F. Huntington, Helen Parry, Suchitra Sundaram, Alan Skarbnik, Manali Kamdar, Ryan Jacobs, Harriet Walter, Renata Walewska, Angus Broom, Sonia Lebowitz, Krista M. Isaac, Craig A. Portell, Inhye E. Ahn, Chaitra S. Ujjani, Mazyar Shadman, Sigrid S. Skånland, Elise A. Chong, Anthony R. Mato

Blood (2021) 138 (18): 1768–1773.

DOI: https://doi.org/10.1182/blood.2021011841

Published: 2021

Includes: Supplemental data

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

DOI: https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Juan Pablo Alderuccio, MD, Adam J Olszewski, MD, Andrew M. Evens, DO,MMSc, Graham P. Collins, MD DPhil, Alexey Danilov, MD, Mark Bower, MD, Deepa Jagadeesh, MDMPH, Catherine Zhu, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, Suchitra Sundaram, MD, Nishitha Reddy, MD, Alessia Dalla Pria, MD, Christopher D'Angelo, MD, Umar Farooq, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Shireen Kassam, MBBS, FRCPath, PhD, Maryam Sarraf Yazdy, MD, Emma Rabinovich, MD, Frank Post, Gaurav Varma, MDMPH, Reem Karmali, MDMSc, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS,MD, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Agrima Mian, MBBS, MD, Bradley Haverkos, MD MPH, MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Paolo F Caimi, MD, Scott E. Smith, MD PhD, Manali Kamdar, MD, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Daniel Rector, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Craig A. Portell, MD, Yong Lin, PhD, Seema Naik, MD, Silvia Montoto, MD, Izidore S. Lossos, MD, Kate Cwynarski

Blood (2020) 136 (Supplement 1): 49–50.

DOI: https://doi.org/10.1182/blood-2020-136989

Published: 2020

Journal Articles

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski, MD, Lasse H. Jakobsen, PhD, Graham P. Collins, MD DPhil, Kate Cwynarski, Veronika Bachanova, MD PhD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Mark Bower, MD, Alessia Dalla Pria, MD, Alexey Danilov, MD, Kevin A. David, MD, Catherine Diefenbach, MD, Fredrik Ellin, MD PhD, Narendranath Epperla, MDMS, Umar Farooq, MD, Tatyana A. Feldman, MD, Alina S. Gerrie, MD MPH, Deepa Jagadeesh, MDMPH, Manali Kamdar, MD MD, Reem Karmali, MDMSc, Shireen Kassam, MBBS, FRCPath, PhD, Vaishalee P. Kenkre, MD, Nadia Khan, MD, Andreas Klein, MD, Izidore S. Lossos, MD, Matthew A. Lunning, DO, FACP, Peter Martin, FRCPC, MD MS, Nicolas Martinex-Calle, Silvia Montoto, MD, Seema Naik, MD, Neil Palmisiano, MDMS, David Peace, MD, Elizabeth H Phillips, MBBS, BSc, Tycel J. Phillips, MD, Craig A. Portell, MD, Nishitha Reddy, MD, Anna Santarsieri, MBBS, Maryam Sarraf Yazdy, MD, Knut B. Smeland, Scott E. Smith, MD PhD, Stephen D. Smith, MD, Suchitra Sundaram, MD, Parameswaran Venugopal, MD, Adam Zayac, MD, Xiao-Yin Zhang, PhD, Catherine Zhu, Chan Yoon Cheah, MBBS, Tarec Christoffer El-Galaly, Andrew M. Evens, DO,MMSc

Blood (2020) 136 (Supplement 1): 46–49.

DOI: https://doi.org/10.1182/blood-2020-134985

Published: 2020

NARROW

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

A cauldron of choices

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only